Valuation: VolitionRx Limited

Market Cap 11.2M 9.83M 9.07M 8.38M 15.89M 1.07B 16.21M 109M 42.38M 525M 42.08M 41.15M 1.82B P/E 2026 *
-0.6x
P/E 2027 * -0.97x
Enterprise Value 11.2M 9.83M 9.07M 8.38M 15.89M 1.07B 16.21M 109M 42.38M 525M 42.08M 41.15M 1.82B EV / Sales 2026 *
4.52x
EV / Sales 2027 * 1.95x
Free-Float
91.38%
Yield 2026 *
-
Yield 2027 * -
1 day-3.93%
1 week-1.10%
Current month-0.37%
1 month-3.24%
3 months-61.55%
6 months-81.05%
Current year-73.69%
1 week 1.25
Extreme 1.25
1.48
1 month 1.17
Extreme 1.17
1.56
Current year 1.17
Extreme 1.17
7.73
1 year 1.17
Extreme 1.17
16
3 years 1.17
Extreme 1.17
31
5 years 1.17
Extreme 1.17
82.8
10 years 1.17
Extreme 1.17
136.8
Manager TitleAgeSince
Chief Executive Officer 55 05/10/2011
Director of Finance/CFO 56 31/01/2021
Chief Tech/Sci/R&D Officer 49 31/03/2024
Director TitleAgeSince
Director/Board Member 55 05/10/2011
Director/Board Member 77 05/10/2011
Director/Board Member 64 08/10/2019
Date Insider Type Main position Quantity % Market Cap.
03-16Tax

Executive/Senior Manager

5,251 0.0039%
03-16Tax

General Counsel

7,003 0.0052%
03-16Tax

Chief Technology Officer

5,310 0.0039%
Change 5-day change 1-year change 3-year change Capi.($)
-3.93%-1.10%-90.47%-95.13% 11.2M
-0.07%-6.23%+111.14%+136.69% 4.48B
-3.17%-9.88%+71.72%+233.77% 3.23B
-0.95%-6.92%-30.75%-41.82% 1.94B
-1.61%+7.81%+141.81%-40.88% 1.91B
-2.68%-5.81%+43.12%+173.04% 1.42B
-3.58%-1.57%-9.16%+45.39% 852M
-2.70%-6.34%+108.70%-52.71% 850M
-8.72%-15.59%-5.65% - 447M
-1.61%-0.96%-36.68%-17.99% 479M
Average -2.90%-3.71%+30.38%+37.82% 1.56B
Weighted average by Cap. -1.88%-4.67%+68.24%+94.81%

Financials

2026 *2027 *
Net sales 2.48M 2.17M 2.01M 1.85M 3.51M 237M 3.58M 24.12M 9.37M 116M 9.3M 9.1M 403M 5.73M 5.03M 4.64M 4.29M 8.13M 549M 8.29M 55.81M 21.69M 269M 21.53M 21.06M 933M
Net income -22.2M -19.47M -17.98M -16.61M -31.49M -2.13B -32.12M -216M -83.98M -1.04B -83.38M -81.55M -3.61B -19.62M -17.21M -15.89M -14.68M -27.83M -1.88B -28.38M -191M -74.21M -919M -73.68M -72.06M -3.19B
Net Debt - -
Logo VolitionRx Limited
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Employees
67
Date Price Change Volume
08/07/26 US$1.345 -3.93% 225,175
07/07/26 US$1.400 +3.70% 296,737
06/07/26 US$1.350 -3.57% 176,076
02/07/26 US$1.400 +2.94% 208,730
01/07/26 US$1.360 +0.74% 201,077
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.345USD
Average target price
16.97USD
Spread / Average Target
+1,161.41%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VNRX Stock